Obstructive Jaundice Due to Duodenal Ulcer Induced by Lenvatinib Therapy for Hepatocellular Carcinoma
-
- Suoh Maito
- Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan
-
- Hagihara Atsushi
- Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan
-
- Yamamura Masafumi
- Department of Gastroenterology, Graduate School of Medicine, Osaka City University, Japan
-
- Maruyama Hirotsugu
- Department of Gastroenterology, Graduate School of Medicine, Osaka City University, Japan
-
- Taira Koichi
- Department of Gastroenterology, Graduate School of Medicine, Osaka City University, Japan
-
- Enomoto Masaru
- Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan
-
- Tamori Akihiro
- Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan
-
- Fujiwara Yasuhiro
- Department of Gastroenterology, Graduate School of Medicine, Osaka City University, Japan
-
- Kawada Norifumi
- Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan
この論文をさがす
抄録
<p>An 82-year-old man with hepatocellular carcinoma presented with upper abdominal pain, vomiting, and jaundice. He had been taking a standard lenvatinib dose for three months. Although acute cholangitis was suggested, imaging studies failed to detect the biliary obstruction site. An endoscopic examination following discontinuation of lenvatinib and aspirin revealed multiple duodenal ulcers, one of which was formed on the ampulla of Vater and causing cholestasis. Endoscopic biliary drainage and antibiotics improved concomitant Enterobacter cloacae bacteremia. Ulcer healing was confirmed after rabeprazole was replaced with vonoprazan and misoprostol. Our case shows that lenvatinib can induce duodenal ulcers resulting in obstructive jaundice. </p>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 60 (4), 545-552, 2021-02-15
一般社団法人 日本内科学会